ESMO 2018 | CheckMate 032: nivolumab/ipilimumab for urothelial carcinoma

Jonathan Rosenberg

Jonathan Rosenberg, MD, of Memorial Sloan Kettering Cancer Center, New York City, NY, discusses results from the Phase I/II CheckMate 032 trial (NCT01928394), where the nivolumab/ipilimumab combination was compared with nivolumab monotherapy in urothelial carcinoma. A higher dose of ipilimumab in the combination therapy seemed to result in improved anti-cancer activity compared to nivolumab alone; however, Dr Rosenberg advises caution as the data is immature. This video was recorded at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany.

Share this video